Daiichi Sankyo Hypertension Drug Olmetec Posts Double Digit Sales
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo announced Oct. 30 results for fiscal quarters ending September 30, and the company's domestic prescription drug sales increased by 4 percent to ¥213.2 billion